What actually makes automation “stick” in cell therapy manufacturing? Is it the tech… or the trust?

In Episode 4 of Cell Mates, Fred sits down with Mary-Ann Santos from Thermo Fisher Scientific to unpack the real adoption flywheel: belief, fear, data, and the moment everything clicks when you see a robot run a process with your own eyes.

They go deep on why modular automation scales faster than “all-in-one” systems, how instrument design can make or break robotics integration, and why the most regulated environments are often the ones where robots shine the brightest (repeatability + sterility, plus, yes, robots don’t breathe).

Highlights include:

• The adoption flywheel: what speeds automation up (and what slows it down)
• Why data beats vibes: building confidence with peer-reviewed performance + demos
• Modular vs all-in-one systems: throughput, bottlenecks, and future-proofing
• “Robot-friendly” instruments: what makes automation easy vs painful
• GMP, sterility, and why humans (lovingly) are a contamination risk
• The next decade: decentralized manufacturing… and what still has to be true for GMP

This episode is about one thing: getting therapies to patients faster without blowing up quality, process trust, or regulatory reality.

New to Cell Mates? We’re the podcast where pharma, robotics, and automation collide to reimagine the future of medicine—one operation at a time.